MOMETASONE/ OLOPATADINE NASAL SPRAY (Ryaltris ®)
Clinical Indication
Moderate to severe nasal symptoms associated with allergic rhinitis
Comments
Third line choice in line with local allergic rhinitis pathway.
Date of classification
May 2025
Green
Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.